Prescient Therapeutics expanded its PTX-100 Phase 2a trial globally and enhanced understanding of its drug’s mechanism through CSIRO collaboration, while cash reserves rose to $11.93 million after a $4.3 million R&D tax refund.
- Global expansion to 12 Phase 2a trial sites with 18 patients enrolled
- CSIRO collaboration reveals strong target binding of PTX-100
- Cash and term deposits total $11.93 million after R&D tax refund
- Deferred R&D invoices expected to impact next quarter’s cash flow
- Cell therapy business development discussions continue
Phase 2a Trial Accelerates with Global Site Growth
Prescient Therapeutics (ASX:PTX) has ramped up enrolments and site activations in its Phase 2a PTX-100 trial, expanding its global footprint to 12 active sites as of April 2026, with expectations to reach up to 16 sites in Europe. The quarter saw six new patient enrolments, bringing the total to 12 by 31 March, with an additional six patients enrolled shortly after, spanning the United States, Australia, and Italy. The trial aims to enrol up to 40 patients, targeting relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), a rare and challenging cancer subtype.
This expansion builds on earlier regulatory wins and trial activations, including the European Medicines Agency’s Orphan Drug Designation and trial approvals, which facilitated the Italian site activations. The growing patient cohort and geographic spread underline Prescient’s commitment to advancing PTX-100’s clinical development on multiple continents simultaneously, following the momentum from its previous global trial expansion with 10 sites and regulatory milestones.
CSIRO Collaboration Deepens Understanding of PTX-100’s Mechanism
These findings complement encouraging safety and efficacy signals observed in earlier Phase 1 and 1b studies, where PTX-100 demonstrated durable clinical benefit, including one patient on compassionate use for over two years. The Phase 1b study has now fully closed following the clinical study report, marking a transition to more advanced trials.
Financial Position Bolstered by R&D Tax Refund and Deferred Costs
Prescient closed the quarter with $11.93 million in cash and term deposits, up from $9.40 million at the end of December 2025. This increase was driven by a $4.3 million R&D tax refund received in January 2026, partially offset by operating cash outflows of $2.21 million. Notably, research and development payments were lower than forecast due to invoice timing delays from a key clinical services provider; these deferred costs are expected to be settled in the June quarter, which may impact future cash flow figures.
The company’s operating expenses included $80,000 in fees to non-executive directors. Prescient’s financial discipline and ongoing funding runway, estimated at over five quarters based on current cash burn, position it to sustain clinical activities as it advances PTX-100 development. This follows earlier capital raises that strengthened its balance sheet, including a $9.85 million raise in late 2025 that supported accelerated trial activity and regulatory progress amid rising losses and capital raise.
Cell Therapy Platforms and Business Development Updates
Beyond PTX-100, Prescient continues to develop its OmniCAR and CellPryme cell therapy platforms. OmniCAR offers a modular, universal immune receptor system enabling controllable T-cell targeting, while CellPryme technologies aim to enhance CAR-T cell expansion and tumour penetration. Business development discussions with potential partners for these platforms progressed during the quarter, though no material outcomes were reported yet.
Prescient plans to update the market on these programs as developments arise, reflecting a diversified pipeline strategy that complements its targeted oncology therapies.
Bottom Line?
While Prescient’s PTX-100 trial gains global traction and scientific backing, deferred R&D costs and ongoing business development outcomes will influence near-term financial visibility.
Questions in the middle?
- How will the settlement of deferred R&D invoices affect Prescient’s cash runway in the next quarter?
- What factors will determine the pace and scale of further patient enrolments in the Phase 2a trial?
- When might Prescient announce partnerships or licensing deals for its OmniCAR and CellPryme platforms?